Benderska-Soder, Natalya and Ecke, Thorsten and Kleinlein, Lisa and Roghmann, Florian and Bismarck, Ekkehardt and van Rhijn, Bas W. G. and Stenzl, Arnulf and Witjes, Johannes Alfred and Todenhoefer, Tilman and Hakenberg, Oliver W. and Grimm, Marc Oliver and Goebell, Peter J. and Burger, Maximilian and Jensen, Jorgen Bjerggaard and Schmitz-Draeger, Bernd J. (2024) Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 42 (8). pp. 229-235. ISSN 1078-1439, 1873-2496
Full text not available from this repository.Abstract
A plethora of urine markers for the management of patients with bladder cancer has been developed and studied in the past. However, the clinical impact of urine testing on patient management remains obscure. The goal of this manuscript is to identify scenarios for the potential use of molecular urine markers in the follow-up of patients with high -risk non -muscle -invasive BC (NMIBC) and estimate potential risks and benefits. Information on the course of disease of patients with high -risk NMIBC and performance data of a point -of -care test (UBC rapid (TM)), an MCM-5 directed ELISA (ADXBLADDER (TM)), and 2 additional novel assays targeting alterations of mRNA expression and DNA methylation (Xpert bladder cancer monitor (TM), Epicheck (TM)) were retrieved from high -quality trials and/or meta -analyses. In addition, the sensitivity of white light cystoscopy (WLC) and the impact of a urine marker result on the performance of WLC were estimated based on fluorescence cystoscopy data and information from the CeFub trial. This information was applied to different scenarios in patient follow-up and sensitivity, estimated number of cystoscopies, and the numbers needed to diagnose were calculated. The sensitivity of guideline -based regular follow-up (SOC) at 1 year was calculated at 96%. For different marker -supported strategies sensitivities ranging from 77% to 97.9% were estimated. Calculations suggest that several strategies are effective for the SOC. While for the SOC 24.6 WLCs were required to diagnose 1 tumor recurrence (NND), this NND dropped below 5 in some marker -supported strategies. Based on the results of this simulation, a marker -supported follow-up of patients with HR NMIBC is safe and offers the option to significantly reduce the number of WLCs. Further research focusing on prospective randomized trials is needed to finally find a way to implement urine markers into clinical decision -making. (c) 2024 Published by Elsevier Inc.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PHOTODYNAMIC DIAGNOSIS; COST-EFFECTIVENESS; VOIDED-URINE; CYSTOSCOPY; CYTOLOGY; Urinary tumor markers; Bladder cancer; High grade; Follow-up; Surveillance; Disease management |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Jan 2026 09:10 |
| Last Modified: | 15 Jan 2026 09:10 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65269 |
Actions (login required)
 |
View Item |
